To analyze the effect of Shensong Yangxin capsule combined with metoprolol in the treatment of coronary heart disease complicated with ventricular arrhythmia.

A total of 100 patients with coronary heart disease and ventricular arrhythmia were divided into control group and observation group according to random number table method, 50 cases in each group. All patients received basic treatment. On this basis, the control group was given metoprolol capsule orally. The observation group was given Shensong Yangxin capsule on the basis of the control group. All patients were treated for 8 weeks. Routine 12-lead electrocardiogram and 24-hour dynamic electrocardiogram were performed before treatment, 4 weeks after treatment and 8 weeks after treatment, respectively. The QTc dispersion (QTcd), short ventricular tachycardia (VT) and ventricular premature contraction (VPC) were detected and compared between the two groups at each time point of treatment. The occurrence of adverse reactions during treatment was recorded.

The total effective rate of the observation group was higher than that of the control group (P<0.05). After 4 weeks and 8 weeks of treatment, the QTcd value, the number of short ventricular tachycardia and the number of premature ventricular contractions of the two groups were lower than those before treatment, and the decrease of the observation group was higher than that of the control group (P<0.05). The incidence of adverse reactions of the two groups was lower than that of the control group (P<0.05). There was no significant difference (P>0.05).

Using metoprolol combined with Shensong Yangxin capsule in the treatment of coronary heart disease with ventricular arrhythmia, the electrophysiological characteristics of the heart were significantly improved, action potential was prolonged, the therapeutic effect was better than metoprolol alone, and the safety was good.